Overview

Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients

Status:
Terminated

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if pralatrexate extends response and survival following CHOP-based chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone) and if pralatrexate improves response in patients with partial response following CHOP-based chemotherapy. Patients will either receive pralatrexate or be under observation. All patients will receive vitamins B12 and folic acid and attend regular clinic visits to evaluate their disease and health.

Phase:

Phase 3

Details

Lead Sponsor:

Spectrum Pharmaceuticals, Inc

Treatments:

10-deazaaminopterin
Aminopterin